Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
27.18
-0.39 (-1.41%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $56.99M in the twelve months ending March 31, 2026, up 97.27% year-over-year. In the year 2025, Tango Therapeutics had annual revenue of $62.38M with 48.29% growth.
Revenue (ttm)
$56.99M
Revenue Growth
+97.27%
P/S Ratio
68.98
Revenue / Employee
$416,000
Employees
137
Market Cap
3.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.38M | 20.32M | 48.29% |
| Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
| Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
| Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
| Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
| Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
| Dec 31, 2019 | 24.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTNGX News
- 16 days ago - Tango Therapeutics price target raised to $40 from $36 at Mizuho - TheFly
- 18 days ago - Tango Therapeutics initiated with an Overweight at JPMorgan - TheFly
- 4 weeks ago - Tango Therapeutics price target raised to $46 from $42 at Canaccord - TheFly
- 5 weeks ago - Tango Therapeutics upgraded to Buy from Hold at Jefferies - TheFly
- 5 weeks ago - Tango Therapeutics Appoints Robert Azelby to Board of Directors - GlobeNewsWire
- 7 weeks ago - Tango Therapeutics 18.2M share Secondary priced at $30.00 - TheFly
- 7 weeks ago - Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - GlobeNewsWire
- 7 weeks ago - Tango Therapeutics price target raised to $66 from $27 at H.C. Wainwright - TheFly